Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle
AssigneeSanofi-Aventis
InventorsGerard Alaux, Estelle Chouin, Nathalie Dufresne-Arokiassamy
Life of this patent
Estimating the term…
Abstract
The disclosure concerns a pharmaceutical composition in the form of a gastric resident matrix tablet, comprising an active principle, characterized in that when contacted with an environment representing gastric fluid, it increases after 15 minutes in volume, by a swelling of at least 200%.
Claims26
A pharmaceutical composition in the form of a gastric retention matrix tablet comprising an active ingredient, where upon contact with a medium representative of the gastric fluid, said tablet increases in volume, after fifteen minutes, by a degree of swelling of at least 200%.
A pharmaceutical composition in the form of a gastric retention matrix tablet having one or more phases comprising an active ingredient, where upon contact with a medium representative of the gastric fluid, said tablet increases in volume, after fifteen minutes, by a degree of swelling of at least 200%, wherein at least one of the phases contains at least, as excipients:
- a) povidone and/or polyvinyl acetate in proportions ranging from 30 to 80% by weight of the phase,
- b) crospovidone or another superdisintegrant chosen from low-substituted hydroxypropyl cellulose (L-HPC), sodium carboxymethyl starch and/or sodium croscarmellose or a combination of said crospovidone and said superdisintegrant in proportions ranging from 5 to 25% by weight of the phase, and
- c) carbomer in proportions ranging from 5 to 40% by weight of the phase.
Dependencies are inferred from the claim text.